Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is set to witness a CAGR of more than 4.5% during the forecast period 2022-2027. The market is estimated to reach a value of more than USD 862 million by 2027.

The COVID-19 pandemic positively impacted the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. In the current crisis, type 2 diabetes patients are at much higher risk.

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. The use of DPP4 inhibitors in patients with COVID-19 with or even without type 2 diabetes offers a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.

The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, nearly 10% of the population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, accounting for nearly 90% of the total diabetic population in 2021.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsTradjenta Segment Occupied the Highest Market Share in the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market in 2021

Tradjenta drug held the highest share in 2021, with a revenue of more than USD 187 million in the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market.

Tradjenta is a prescription drug approved by the Food and Drug Administration (FDA) to help improve blood glucose control in adults with type 2 diabetes and is considered an adjunct treatment to diet and exercise. It is also used as an add-on therapy to insulin. Tradjenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). Boehringer Ingelheim Pharmaceuticals, Inc. offers a Tradjenta Savings card, and eligible commercially insured patients 18 years or older pay as little as USD 10/month with a maximum savings of up to USD 150. Offer not valid for patients without commercial coverage or patients whose prescriptions for TRADJENTA are eligible to be reimbursed, in whole or in part, by any governmental program such as Medicaid, Medicare, Medigap, the Retiree Drug Subsidy Program, VA, DOD, TRICARE, or any state patient or pharmaceutical assistance program.

According to IDF Diabetes Atlas 2021, the prevalence of diabetes in Mexico has now reached 16.9% or one in six adults. In 2021, an estimated 14 million adults in Mexico are living with diabetes – a rise of 10% in the past two years. Additionally, 11 million adults in the country have Impaired Glucose tolerance (IGT), which places them at high risk of developing type 2 diabetes. Diabetes-related health expenditure in Mexico has reached USD 20 billion, putting it in the top ten countries or territories with the highest total health expenditure. Under half (47.5%) of people living with diabetes in the country are undiagnosed.

Lack of health insurance deprived the poor of access to services and put them at risk of financial hardship. To protect the people against excessive health expenditures, many countries like Mexico have implemented mechanisms such as community-based health insurance, national health insurance, and targeted public health insurance. Mexico has multiple health insurance providers. The Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado [State Employee’s Social Security and Social Services Institute, ISSSTE] provides coverage for government employees, and the Instituto Mexicano del Seguro Social [Mexican Social Security Institute, IMSS] covers for private-sector employees. The Seguro Popular [People’s Insurance] was launched to protect the working-age population against steep healthcare costs. Enrolment in the Seguro Popular is independent of health status or pre-existing illness, there is no co-payment in accordance with the type of health care received, and family contributions are determined solely by the ability to pay. The various initiatives by the Mexican government are expected to drive the market’s growth.

Brazil is Expected to Dominate the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market

Brazil holds the highest market share in the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market and is also expected to register a CAGR of more than 5% in the forecast period.

According to IDF Diabetes Atlas 2021, 15.7 million adults about 10.5% are currently living with diabetes in Brazil – or one in ten adults. The cost of diabetes-related health expenditure in Brazil is the third highest in the world, at 42.9 billion USD. In addition, 18 million adults around 11.9% have Impaired Glucose Tolerance which places them at high risk of developing type 2 diabetes. 32% of people living with diabetes in Brazil are undiagnosed. Additional data on glycaemic control in Brazil show that only 25% met the therapeutic goal of glycated hemoglobin (HbA1c) less than 7% before the pandemic, as recommended by the Brazilian Diabetes Society (SBD).

When diabetes is undetected or inadequately treated, people with diabetes are at risk of serious and life-threatening complications, such as heart attack, stroke, kidney failure, blindness, and lower-limb amputation. These result in reduced quality of life and higher healthcare costs and lead to a greater need for access to care. Brazil has implemented a set of reforms over the past to improve the distribution of doctors, develop new forms of the service organization, introduce new financing models, and implement a range of quality improvement initiatives and policy frameworks to overcome risk factors such as obesity and emerging pandemic threats.

According to IDF, the rise in the number of people with type 2 diabetes in Brazil is driven by several socio-economic, demographic, environmental, and genetic factors including urbanization, an aging population, decreasing levels of physical activity, and increasing levels of people being overweight and developing obesity. The prevalence of diabetes is growing among all ages in Brazil. ​Diabetes mellitus has been of wide concern with its high prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments. The various initiatives by the Brazilian government are expected to drive the market’s growth. The Government has partnered with numerous private companies to utilize their supply chain (manufacturing, distribution, and retailers) to ensure low prices for drugs.

Competitive Landscape

The Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Merck, Boehringer Ingelheim and Novartis while the remaining market comprises other local or region-specific manufacturers.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.